The role of clofarabine in acute myeloid leukemia

References

• Parker WB, Allan PW, Hassan AE, . Antitumor activity of 2- fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003;10:23–29.
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Esparza LM, . Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970–2974.
   PubMed Web of Science ®Google Scholar
• Lotfi K, Mansson E, Spasokoukotskaja T, . Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438–2444.
   PubMed Web of Science ®Google Scholar
• Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847–2852.
   PubMed Web of Science ®Google Scholar
• Pui CH, Jeha S. Clofarabine. Nat Rev Drug Discov2005(Suppl.): S12–S13.
   Google Scholar
• Parker WB, Shaddix SC, Chang CH, . Effects of 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991;51: 2386–2394.
   PubMed Web of Science ®Google Scholar
• Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996;56:3030–3037.
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, . Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537–3543.
   PubMed Web of Science ®Google Scholar
• Parker WB, Shaddix SC, Rose LM, . Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999;55:515–520.
   PubMed Web of Science ®Google Scholar
• Parker WB, Bapat AR, Shen JX, . Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988;34: 485–491.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kanazawa J, Akinaga S, . Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43: 233–240.
   PubMed Web of Science ®Google Scholar
• Waud WR, Schmid SM, Montgomery JA, . Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000;19: 447–460.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Plunkett W. Metabolism of 9-beta-D-arabinosyl- 2-fluoroadenine-5′-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1983;1:1–10.
   PubMedGoogle Scholar
• Response of subcutaneous HT-29 tumor to clofarabine or CPT-11 (Final report ILEX 27). Birmingham, AL: Southern Research Institute;2003.
   Google Scholar
• Clofarabine investigator's brochure, 6th ed. Final report. San Antonio, TX: Genzyme Corp.; 2007.
   Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, . Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kantarjian H, Faderl S, . Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9:6335–6342.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, . Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988;48:329–334.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Iacoboni S, Estey E, . Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985;12:20–30.
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Dixon D, . Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580–583.
   PubMed Web of Science ®Google Scholar
• Cooper T, Ayres M, Nowak B, . Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361–368.
   PubMed Web of Science ®Google Scholar
• Moufarij MA, Sampath D, Keating MJ, . Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006;108:4187–4193.
   PubMed Web of Science ®Google Scholar
• Foran JM, Faderl S, Wetzler M, . A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003;22: Abstract 2360.
   Google Scholar
• Racil Z, Toskova M, Dvorakova D, . Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. Am J Hematol 2011 Oct 12. [Epub ahead of print]
   Google Scholar
• Krawczyk J, Ansar N, Swords R, . Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematol Oncol 2010;28: 118–123.
   PubMed Web of Science ®Google Scholar
• Faderl S, Garcia-Manero G, Jabbour E, . A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012;118: 722–728.
   PubMed Web of Science ®Google Scholar
• Faderl S, Garcia-Manero G, Estrov Z, . Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28:2755–2760.
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, . Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940–947.
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, Verstovsek S, . Clofarabine plus cytarabine (ara-C) combination is active in newly diagnosed patients (pts) >= age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 2004;104(Suppl. 1): Abstract 875.
   Google Scholar
• Faderl S, Ravandi F, Huang X, . A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Agura E, Cooper B, Holmes H, . Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011;16:197–206.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, . Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012;118:4471–4477.
   PubMed Web of Science ®Google Scholar
• Becker PS, Kantarjian HM, Appelbaum FR, . Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011;155:182–189.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, . DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580–3589.
   PubMed Web of Science ®Google Scholar
• Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, . Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002;68:370–375.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, . Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113:2090–2096.
   PubMed Web of Science ®Google Scholar
• Nazha A, Ravandi F, Kantarjian HM, . Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia (AML). Blood 2011;118(Suppl. 1): Abstract 1550.
   Google Scholar
• Mathisen M, Kantarjian H, Faderl S, . Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). J Clin Oncol 2012;30(Suppl.): Abstract 6607.
   Google Scholar
• Burnett AK, Kell WJ, Hills RK, . The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A pilot study. Blood 2006;108(Suppl.): Abstract 1950.
   Google Scholar
• Foster MC, Amin C, Voorhees PM, . A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma 2012;53:1331–1337.
   PubMed Web of Science ®Google Scholar
• Amadori S, Stasi R, Martelli AM, . Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012;156: 205–212.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S,: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116:4422–4429.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J, . European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389–2395.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, . Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Faderl S, Wetzler M, Rizzieri D, . Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol 2012;30:2492–2499.
   PubMed Web of Science ®Google Scholar
• Martin MG, Uy GL, Procknow E, . Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009;44: 13–17.
   PubMed Web of Science ®Google Scholar
• Farag SS, Wood LL, Schwartz JE, . Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011;25:599–605.
   PubMed Web of Science ®Google Scholar
• Locke FL, Artz A, Rich E, . Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 2010;45:1692–1698.
   PubMed Web of Science ®Google Scholar
• Buchholz S, Dammann E, Stadler M, . Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012;88: 52–60.
   PubMed Web of Science ®Google Scholar